VIVES is a multi-sector fund that invests in projects with a positive societal impact
3D-Side assists surgeons by integrating 3D technologies into the operating room. They combine the precision of engineering with medical expertise to individualize the surgical treatment of each...
ATB Therapeutics is pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to transform cancer treatment. By combining cutting-edge biotechnology with...
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
Eric de La Fortelle, Venture Partner at Seventure Partners:
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Gael Rouvroy, CEO intoPIX:
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is